Two Nebraska researchers have launched a startup company aimed at bringing to market an innovative method for delivering therapeutics, gene editing tools, plasmids and more to targeted locations in ...
Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies ...
Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOSâ„¢ II ILIM, a quantum cascade laser (QCL) based ...
The new name draws from the company’s nearly two decades of work in ryanodine receptor (RyR) biology, which it has used to ...
Bruker’s LUMOS II FT-IR spectrometer is fully compliant to all pharmaceutical regulations like GLP FDA 21 CFR part 11, cGMP, and all pharmacopoeias. It is the first instrument to offer Ph.Eur.
Veeda Group has unveiled a new logo and brand identity—Veeda Lifesciences—reflecting ... with reputable sponsors, including leading global pharma companies.
Iris Bincovich Innocan Pharma's CEO stated: "I am thrilled with this successful closing of this private placement round, which reflects strong investor confidence in Innocan's long-term vision, ...
President-elect Trump’s plan to enact heavy tariffs on certain imports could affect the prices and availability of pharmaceutical drugs in the U.S. Trump has floated 25 percent tariffs on ...
A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...
A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...